REACH2: Implementation Research on Bi-Annual Mass Distribution of Azithromycin to Children 1-11 Months in Côte d'Ivoire

• Status: Recruiting
• Trial end date: 2024-02-28
• Target enrollment: 0
• Participant gender: All

Summary

REACH2 is a three-year implementation research study designed to examine the implementation through a mass drug administration platform of bi-annual single-dose azithromycin to reduce child mortality among children ages 1 to 11 months who reside in high child mortality settings.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: FHI 360
• Collaborators: Ministry of Health and Public Hygiene (Cote d'Ivoire); Programme National de Lutte contre les Maladies Tropicales Négligées à Chimiothérapie Préventive, Côte d'Ivoire
• Treatments: Azithromycin

Criteria

Inclusion Criteria:

• Ages 1 to 11 months

• Resident in targeted community

Exclusion Criteria:

• Children below 3.0 kg (3rd centile for healthy 1-month old infants in the WHO growth charts)

• Appears seriously ill at the time of the MDA (per the CDD's assessment)

• Unable to swallow liquid delivered through a needle-less syringe because of physical limitations

• Known allergy to macrolides, including azithromycin, based on the primary caregiver's report of prior adverse reaction to medication likely to be a macrolide

• prior allergic reaction to medication likely to be a macrolide